A. Adjei

发表

Very important pharmacogene summary: sulfotransferase 1A1.

R. Altman, T. Klein, R. Weinshilboum, 2009, Pharmacogenetics and genomics.

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

C. Gridelli, D. Ruysscher, K. Kerr, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.

J. Sloan, R. Goldberg, A. Adjei, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.

J. Sloan, J. Sloan, R. Goldberg, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations

T. Rebbeck, C. Haiman, A. Kibel, 2022, medRxiv.

Dietary vitamin D intake and serum 25‐hydroxyvitamin D level in relation to disease outcomes in head and neck cancer patients

A. Adjei, I. Bairati, Geoffrey Liu, 2011, International journal of cancer.

A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.

J. Sloan, R. Goldberg, A. Adjei, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology.

H. Cohen, J. Buckner, J. Mandelblatt, 2020, Journal of geriatric oncology.

Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects.

R. Weinshilboum, A. Adjei, A. Gaedigk, 2008, Birth defects research. Part A, Clinical and molecular teratology.

A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study

J. Jett, S. Mandrekar, S. Hillman, 2007 .

A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer

K. Cease, A. Adjei, D. Trump, 2013, Cancer Chemotherapy and Pharmacology.

Phase II study of perioperative chemotherapy with cisplatin (C) and pemetrexed (P) in non-small cell lung cancer (NSCLC).

A. Adjei, T. Demmy, S. Yendamuri, 2012 .

What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings

J. Buckner, D. Sargent, S. Mandrekar, 2008 .

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

J. Sloan, M. Goetz, A. Adjei, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum Vitamin D Metabolites in Colorectal Cancer Patients Receiving Cholecalciferol Supplementation: Correlation with Polymorphisms in the Vitamin D Genes

Zengrui Wu, A. Adjei, M. Fakih, 2013, Hormones and Cancer.

CATECHOL ESTROGEN METABOLISM : POSSIBLE ROLE FOR SULFATION AND CARCINOGENESIS

R. Weinshilboum, A. Adjei, T. C. Wood, 2022 .

A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study.

S. Mandrekar, N. Foster, M. Aubry, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751

R. Weinshilboum, Wei Zhang, M. Ratain, 2013, Pharmacogenetics and genomics.

Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.

J. Sloan, R. Goldberg, A. Adjei, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)

J. Jett, S. Mandrekar, R. Marks, 2005 .

A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors.

J. Sosman, I. Puzanov, A. Adjei, 2010 .

Sulfate Conjugation: Pharmacogenetics and Pharmacogenomics

R. Weinshilboum, A. Adjei, 2005 .

Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd).

J. Sloan, R. Goldberg, A. Adjei, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules.

J. Jett, S. Mandrekar, A. Adjei, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia

Q. Hu, Song Liu, G. Wilding, 2014, Cancer.

First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.

J. Sosman, A. Ribas, P. LoRusso, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies.

A. Adjei, R. Brekken, B. Tennant, 2019, Archives of biochemistry and biophysics.

Genetic sequence variants in vitamin D metabolism pathway genes, serum vitamin D level and outcome in head and neck cancer patients

A. Azad, A. Adjei, I. Bairati, 2013, International journal of cancer.

Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis.

N. Foster, A. Adjei, K. Olivier, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates

A. Adjei, S. Patnaik, M. Opyrchal, 2019, Molecular Cancer Therapeutics.

Gender Medicine and Oncology: Report and consensus of an ESMO Workshop.

S. Oertelt-Prigione, J. Fellay, G. Coukos, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic Variations and Health-Related Quality of Life (HRQOL): A Genome-Wide Study Approach

D. Schaid, C. Vachon, J. Olson, 2021, Cancers.

Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study

D. Schaid, C. Vachon, J. Olson, 2021, Cancers.

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer

F. Hirsch, W. Franklin, M. Varella‐Garcia, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528

S. Mandrekar, A. Adjei, A. Adjei, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer: A North Central Cancer Treatment Group-Based Exploratory Study

S. Mandrekar, A. Adjei, A. Adjei, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Human SULT1A1 gene: copy number differences and functional implications.

D. Schaid, G. Jenkins, R. Weinshilboum, 2007, Human molecular genetics.

Catecholestrogen sulfation: possible role in carcinogenesis.

R. Weinshilboum, A. Adjei, 2002, Biochemical and biophysical research communications.

2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease

C. Dooms, A. Marchetti, L. Bubendorf, 2014 .

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.

P Baas, C. Dooms, A. Marchetti, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of Resveratrol on 17β-Estradiol Sulfation by Human Hepatic and Jejunal S9 and Recombinant Sulfotransferase 1E1

R. Weinshilboum, A. Adjei, I. Kapetanovic, 2008, Drug Metabolism and Disposition.

Structural basis of substrate recognition in thiopurine s-methyltransferase.

R. Weinshilboum, A. Adjei, Q. Feng, 2008, Biochemistry.

Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics

R. Weinshilboum, E. Wieben, A. Adjei, 2003, British journal of pharmacology.

Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non–Small-Cell Lung Cancer

A. Adjei, T. Demmy, S. Yendamuri, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102

A. Giuliano, P. Novotny, R. Leon-Ferre, 2020, Supportive Care in Cancer.

Human aromatase: gene resequencing and functional genomics.

Eric D Wieben, Richard M Weinshilboum, Liewei Wang, 2005, Cancer research.

Human SULT 1 A 1 gene : copy number differences and functional implications

D. Schaid, G. Jenkins, R. Weinshilboum, 2007 .

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

S. Mandrekar, D. Gandara, A. Adjei, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422).

N. Foster, A. Adjei, K. Rowland, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of cetuximab and radiation in elderly and / or poor performance status patients with locally advanced non-small-cell lung cancer ( N 0422 )

N. Foster, A. Adjei, K. Rowland, 2010 .

Prophylactic cranial irradiation in small-cell lung cancer: Findings from a North Central Cancer Treatment Group Pooled Analysis.

N. Foster, A. Adjei, K. Olivier, 2012 .

A pooled analysis of 11 NCCTG advanced stage non-small cell lung cancer (NSCLC) trials reveals the importance of baseline blood counts on clinical outcomes

J. Jett, S. Mandrekar, S. Hillman, 2005 .

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.

J. Jett, S. Mandrekar, M. Aubry, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.

J. Sloan, R. Goldberg, A. Adjei, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study

S. Mandrekar, D. Gandara, A. Adjei, 2008 .

Identification and characterization of genetic variation in the folylpolyglutamate synthase gene.

A. Adjei, A. Adjei, G. Dy, 2007, Cancer research.

Estrogen Bioactivation, Genetic Polymorphisms, and Ovarian Cancer

R. Vierkant, T. Sellers, V. Pankratz, 2005, Cancer Epidemiology Biomarkers & Prevention.

A phase II NCCTG/CALGB trial of imatinib (STI571) in patients (pts) with c-kit-expressing relapsed small cell lung cancer (SCLC)

J. Jett, S. Mandrekar, M. Aubry, 2005 .

Human phenylethanolamine N‐methyltransferase pharmacogenomics: gene re‐sequencing and functional genomics

R. Weinshilboum, Liewei Wang, E. Wieben, 2005, Journal of neurochemistry.

A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamycin (17-AAG) and cisplatin (CDDP) in solid tumor patients.

S. Mandrekar, A. Adjei, C. Erlichman, 2004, Journal of Clinical Oncology.

The Results of combined modality therapy for limited stage small cell lung cancer (LD-SCLC) in the elderly.

J. Jett, S. Mandrekar, A. Adjei, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of the combination of erlotinib and tipifarnib in patients with advanced solid tumors

S. Mandrekar, R. Marks, A. Adjei, 2005 .

Safety and tolerability of the anti-IGF-I receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in patients with advanced solid tumors

A. Adjei, A. Gualberto, M. Pollak, 2007 .

NCCTG N0821 (Alliance): A Phase II First-Line Study of Pemetrexed, Carboplatin, and Bevacizumab in Elderly Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer With Good Performance Status

S. Mandrekar, M. Aubry, A. Adjei, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Complementary and alternative medicine (CAM) use by patients enrolled in phase I clinical trials

J. Sloan, S. Mandrekar, A. Adjei, 2004 .

A phase I dose escalation study of irinotecan (CPT-11), oxaliplatin (Oxal), and capecitabine (Cap) within three UGT1A1 TA promoter cohorts (6/6, 6/7, and 7/7)

S. Mandrekar, M. Goetz, R. Goldberg, 2005 .

A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).

S. Mandrekar, A. Adjei, G. Dy, 2010 .

Metaplastic breast cancer: prognosis and response to systemic therapy.

J. Ingle, A. Adjei, V. Suman, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors

A. Adjei, P. Haluska, T. Yap, 2007 .

Prevalence and clinical association of MET gene amplification in patients with NSCLC: results from the ETOP lungscape project

A. Warth, H. Dienemann, A. Marchetti, 2015 .

Age, gender, performance status and stage outperformed stage alone in predicting overall survival (OS) in patients with small cell lung cancer: A pooled analysis of 1,623 patients from the North Central Cancer Treatment Group

J. Jett, S. Mandrekar, N. Foster, 2007 .

Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib.

J. Sosman, I. Puzanov, A. Adjei, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human 3'-phosphoadenosine 5'-phosphosulfate synthetase: radiochemical enzymatic assay, biochemical properties, and hepatic variation.

R. Weinshilboum, A. Adjei, A. Adjei, 2001, Drug metabolism and disposition: the biological fate of chemicals.

6603 A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G)

A. Hutson, A. Adjei, M. Fakih, 2009 .

Should attribution be considered when interpreting adverse event data: A North Central Cancer Treatment Group (NCCTG) evaluation of a phase III placebo controlled trial.

E. Perez, J. Buckner, D. Sargent, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.